Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Yahong Meditech Co Ltd (688176.SS)
Shanghai, CN
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.22% | -9.03% | -11.51% | -6.34% | +11.79% | -1.13% | +28.73% | -17.60% | -35.34% | -35.34% | -35.34% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+37.5% ★ Q1'26: +16.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-10.3% Q1'26: -33.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-170.9% Q1'26: -180.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-157.5% Q1'26: -157.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-98.8% Q1'26: -109.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-5.4% ★ Q1'26: -5.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.77× Q1'26: -0.76× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
26.1K
est: 2.50M (-99.0%)
|
13.75M
est: 94.17M (-85.4%)
|
201.56M
est: 165.00M (+22.2%)
|
277.12M
est: 277.00M (+0.0%)
|
507.00M
504.00M – 510.00M
+83.0% YoY
|
801.00M
800.00M – 802.00M
+58.0% YoY
|
1.15B
1.14B – 1.15B
+43.2% YoY
|
| EBITDA |
-240.39M
est: -1.50M (-15,925.8%)
|
-390.51M
est: -94.17M (-314.7%)
|
-364.77M
est: -165.00M (-121.1%)
|
-421.37M
est: -277.00M (-52.1%)
|
-507.00M
-510.00M – -504.00M
-83.0% YoY
|
-801.00M
-802.00M – -800.00M
-58.0% YoY
|
-1.15B
-1.15B – -1.14B
-43.2% YoY
|
| EBIT |
-244.50M
est: -1.50M (-16,199.9%)
|
-398.54M
est: -94.17M (-323.2%)
|
-379.76M
est: -165.00M (-130.2%)
|
-436.36M
est: -277.00M (-57.5%)
|
-507.00M
-510.00M – -504.00M
-83.0% YoY
|
-801.00M
-802.00M – -800.00M
-58.0% YoY
|
-1.15B
-1.15B – -1.14B
-43.2% YoY
|
| Net Income |
-246.55M
est: -260.11M (+5.2%)
|
-400.43M
est: -385.58M (-3.9%)
|
-384.06M
est: -458.48M (+16.2%)
|
-419.34M
est: -408.16M (-2.7%)
|
-387.50M
-424.93M – -335.47M
+5.1% YoY
|
-209.67M
-212.47M – -206.87M
+45.9% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
88.29M
est: 4.07B (-97.8%)
|
117.55M
est: 326.89B (-100.0%)
|
262.75M
est: 572.77B (-100.0%)
|
215.21M
est: 961.56B (-100.0%)
|
1.76T
1.75T – 1.77T
+83.0% YoY
|
2.78T
2.78T – 2.78T
+58.0% YoY
|
3.98T
3.97T – 3.99T
+43.2% YoY
|
| EPS |
-0.43
est: -0.46 (+6.5%)
|
-0.70
est: -0.69 (-1.5%)
|
-0.68
est: -0.82 (+17.1%)
|
-0.75
est: -0.73 (-2.7%)
|
-0.68
-0.76 – -0.60
+6.8% YoY
|
-0.38
-0.38 – -0.37
+44.9% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baohua Chen | Executive Vice President of Finance | — | male |
| Chen Yu | Senior Vice President of Biological Research, Drug Discovery Division & Head of Translational Medicine Research | — | — |
| Chengfeng Zhuang | Deputy GM & Director | — | male |
| David Wilson | Senior Vice President of Business Development | — | — |
| Haiyao Hu | Accounting Supervisor | — | — |
| Ke Pan | Founder, Chairman & Chief Executive Officer | — | — |
| Mingyuan Yang | Financial Manager, Board Secretary & Director | — | male |
| Ningshu Liu | Chief Scientific Officer | — | — |
| Yang Zhao | Senior Vice President of Business Development | — | male |
| Ying Xu | Chief Business Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688176.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
